B_B schreef:
Een overname is zeker!
Tot de overname blijft de koers tussen de 14 en 16 euro.
Geduld, het duurt niet lang meer.
Insider Trading:
05/02/09 J.P. Oosterveld
Aank. aandelen 2.500 15,99 EUR 39.975,00 EUR
05/02/09 Ph. M. Satow
Aank. aandelen 2.500 15,99 EUR 39.962,50 EUR
05/02/09 C. Wilhelmsson
Aank. aandelen 2.500 15,99 EUR 39.975,00 EUR
05/02/09 A. Hoevenaars
Aank. aandelen 2.500 15,99 EUR 39.975,00 EUR
05/02/09 S. Davis
Aank. aandelen 5.000 15,99 EUR 79.950,00 EUR
05/02/09 S. Lance
Aank. aandelen 12.500 15,99 EUR 199.875,00 EUR
vergelijk press releases met vorig jaar:
2009
26 Feb 2009 Crucell's Revolutionary Antibody for Universal Therapy Against Flu
10 Feb 2009 DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6® Cell Line Proteins
05 Feb 2009 Crucell Announces Profits for Full Year 2008
04 Feb 2009 Crucell to Release Q4 & FY 2008 Results on Thursday, February 5, 2009
26 Jan 2009 Discussions on a Combination of Crucell and Wyeth Discontinued
07 Jan 2009 Crucell and Wyeth in discussion on a combination of the two companies
06 Jan 2009 Crucell Announces STAR® Research and Commercial License Agreement with Centocor, Inc.
2008
29 Apr 2008 Crucell Announces STAR® Research License Agreement with Toyobo Gene Analysis Co. LTD.
09 Apr 2008 Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
08 Apr 2008 Crucell Announces STAR® Research License Agreement with Celltrion, Inc.
03 Apr 2008 Crucell Announces First in Man Study with New Adenovirus Vector
31 Mar 2008 Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
25 Mar 2008 Crucell Announces STAR® Research License Agreement with Medarex Inc
17 Mar 2008 Crucell and DSM Biologics Announce Additional PER.C6® Licensing Agreement with MorphoSys
12 Mar 2008 Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London
11 Mar 2008 DSM and Crucell Announce PER.C6® Technology Milestone
03 Mar 2008 Crucell Announces Vaccine Development Agreement with Wyeth Pharmaceuticals
12 Feb 2008 Crucell Announces Fourth Quarter and Full Year 2007 Results
11 Feb 2008 Crucell Nominates Cees de Jong as Management Board Member
31 Jan 2008 Crucell to Release Q4/FY 2007 Earnings on Tuesday, February 12, 2008
30 Jan 2008 Crucell Nominates Steve Davis as Supervisory Board Member
16 Jan 2008 Crucell Reacts to Recent CEVEC Press Release
14 Jan 2008 Crucell Announces STAR® Technology Research License with Korean-based ISU ABXIS
09 Jan 2008 TRADING UPDATE
03 Jan 2008 Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies